Does Anthem (Elevance Health) Cover Prolia (Denosumab)?

What Is Prolia (Denosumab) and Why Does Coverage Complexity Exist?

Prolia (denosumab 60 mg subcutaneous, every 6 months) is a fully human monoclonal antibody that inhibits RANK ligand, blocking osteoclast formation and reducing bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high risk of fracture, and label expansions followed for men, glucocorticoid-induced osteoporosis, and androgen-deprivation or aromatase-inhibitor-associated bone loss [1].

The drug's specialty-tier status stems from its price. At roughly $1,500 per injection, annual therapy costs approach $3,000 before rebates. Anthem places high-cost injectables on Tier 4 or Tier 5 specialty formulary positions, which triggers mandatory utilization-management review before claims are paid [2].

Coverage complexity also reflects clinical controversy. Oral bisphosphonates such as alendronate (Fosamax) cost under $10 per month in generic form and carry strong evidence for fracture prevention [3]. Anthem, like most large commercial insurers, asks prescribers to document why a cheaper, guideline-supported alternative cannot be used before authorizing the more expensive agent.

The FREEDOM trial (N=7,808 to 36 months) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68% (relative risk 0.32; 95% CI 0.26 to 0.41; P<0.001), nonvertebral fractures by 20%, and hip fractures by 40% compared with placebo [4]. Those efficacy data are exactly what Anthem's medical directors examine when reviewing prior-authorization requests and appeals.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines list denosumab as a first-line option for patients at very high fracture risk, defined as a T-score at or below -3.0, multiple prior fragility fractures, or very high FRAX probability [5]. Citing that guideline language directly in a PA request substantially strengthens the clinical argument.

How Anthem (Elevance Health) Structures Its Prolia (Denosumab) Prior Authorization

Anthem's prior authorization for Prolia follows a structured clinical checklist. Physicians submit through Anthem's AIM Specialty Health portal or via fax using the CMS-prescribed format. The core clinical criteria typically include [2]:

1. A confirmed diagnosis of osteoporosis (DXA T-score at or below -2.5 at the lumbar spine or femoral neck) or a low-trauma fracture documented by imaging.
2. Prescriber attestation that the patient is a licensed practitioner managing bone health (endocrinology, rheumatology, primary care with bone-density expertise).
3. Step-therapy documentation: evidence that the patient has completed an adequate trial of an oral bisphosphonate (generally alendronate 70 mg weekly or risedronate 35 mg weekly for at least 6 months), or a documented clinical reason why bisphosphonate therapy is contraindicated or not tolerated.
4. Lab values: serum calcium and 25-hydroxyvitamin D within normal limits, or an active plan to correct deficiency before the first injection.
5. Renal function: serum creatinine or estimated GFR, since hypocalcemia risk rises in patients with an eGFR below 30 mL/min/1.73m².

Anthem targets a 3-business-day turnaround for standard PA decisions and 1 business day for urgent requests under CMS and state insurance-department timelines [6]. Many state Anthem subsidiaries (Anthem Blue Cross, Anthem Blue Cross and Blue Shield, Empire BlueCross) operate under state-specific rules that may shorten those windows.

The single most common reason for initial PA denial is incomplete step-therapy documentation. A prescriber who writes only "patient tried alendronate" without specifying dose, duration, and reason for discontinuation will likely receive a denial. The medication-administration record or pharmacy-claims history, attached as supporting documentation, closes that gap.

Anthem Step Therapy for Prolia: What Counts as an Adequate Bisphosphonate Trial?

Step therapy is the contractual requirement that a patient try one or more preferred drugs before the insurer approves the requested agent. Anthem's step-therapy protocol for denosumab generally accepts any of the following as meeting the prior step [2] [3]:

• Alendronate (generic Fosamax) 70 mg oral weekly for at least 6 months with documented inadequate response or intolerance.
• Risedronate (generic Actonel) 35 mg oral weekly or 150 mg monthly for at least 6 months with documented inadequate response or intolerance.
• Ibandronate (generic Boniva) 150 mg oral monthly, though this agent lacks hip-fracture data and Anthem may still require a second step drug in some plans.
• Zoledronic acid (Reclast) 5 mg IV annually: for patients who cannot tolerate oral agents due to esophageal disease or adherence problems, zoledronic acid often satisfies the step-therapy requirement, though some plans list it separately.

"Inadequate response" in practice means either a new fracture on therapy, continued bone mineral density decline of more than 5% at a monitored DXA site, or persistently elevated bone-turnover markers such as serum CTX. "Intolerance" means a documented adverse effect: esophageal ulcer, severe GERD, osteonecrosis of the jaw, atypical femur fracture, or a contraindication such as CrCl below 35 mL/min (the prescribing threshold where oral bisphosphonates carry FDA labeling caution) [1].

Step-therapy bypass criteria recognized by most Anthem plans include [5]:

• FRAX 10-year major osteoporotic fracture probability above 20% or hip-fracture probability above 3% in the context of normal or mildly reduced bone density.
• Prior hip or vertebral fracture (patients are already at very high risk and AACE recommends anabolic or high-potency therapy first).
• Active glucocorticoid use at prednisone-equivalent doses above 7.5 mg/day for 3 or more months (American College of Rheumatology 2022 guidelines support denosumab in this population) [7].
• Renal impairment with eGFR below 35 mL/min.

Anthem Formulary Tier and What You Will Actually Pay for Prolia

Anthem places Prolia on Specialty Tier 4 or Tier 5 across most commercial plans. Tier 4 cost-sharing typically runs 25% to 33% coinsurance after the deductible; Tier 5 (if the plan uses a 5-tier structure) may impose 40% or a flat specialty copay between $150 and $300 per fill [2].

Because Prolia is injected in a physician's office, the benefit may adjudicate under the medical benefit rather than the pharmacy benefit, particularly on many employer-sponsored PPO plans. Under the medical benefit, the drug is billed using HCPCS code J0897 (denosumab injection, 1 mg; a full 60 mg dose = 60 units). Medical-benefit cost-sharing is often lower than specialty-pharmacy cost-sharing for the same drug, making benefit-navigation an important step before dispensing.

Out-of-pocket maximums under the Affordable Care Act cap annual cost-sharing for in-network care. For 2025, the individual OOP maximum is $9,450 for self-only ACA-compliant coverage [8]. Patients who reach that cap pay zero for subsequent Prolia injections in the same plan year.

The Anthem drug formulary is plan-specific and updated quarterly. Prescribers should verify formulary status using the Anthem drug search tool or request a formulary exception if Prolia is excluded from a specific plan's specialty list [6].

How to Appeal an Anthem Denial of Prolia (Denosumab)

Anthem denials arrive with a specific denial reason code and a summary of the clinical criteria that were not met. Reading that denial letter carefully before drafting an appeal saves significant time. Common denial reasons and the corresponding documentation response:

"Step therapy not completed." Attach the pharmacy-claims history showing bisphosphonate fills, an office note documenting the adverse effect or fracture event that occurred during therapy, and a paragraph citing the AACE 2020 guideline recommendation for denosumab in very-high-risk patients [5].

"Medical necessity not established." Attach the DXA report with T-scores, the radiology report for any fragility fracture, the FRAX calculation printout, and a letter of medical necessity from the treating physician referencing the FREEDOM trial efficacy data [4].

"Diagnosis not covered." This arises when an off-label indication is submitted. Confirm that the ICD-10-CM code on the PA request matches an FDA-approved indication: M81.0 (age-related osteoporosis without current pathological fracture), M80.00 (osteoporosis with current pathological fracture, unspecified), or Z79.52 (long-term use of systemic steroids) for glucocorticoid-induced disease [1].

The Three-Level Appeal Process

1. Internal appeal (Level 1). Submit within 180 days of the denial notice. Anthem must decide within 30 days for non-urgent clinical appeals and 72 hours for urgent ones, under federal ERISA and ACA rules [6]. Include all clinical documentation, the physician's letter, and any peer-reviewed references.

2. External review / Independent Review Organization (IRO). If the internal appeal fails, federal law (ACA Section 2719) and most state insurance codes guarantee the right to external review by an IRO not affiliated with Anthem [9]. IRO decisions are binding on the insurer. Studies of IRO decisions for specialty osteoporosis drugs show patient-favorable rates between 40% and 60% when documentation is complete [10].

3. State insurance commissioner complaint. Filing a complaint with the state Department of Insurance does not directly reverse a denial but creates a regulatory record, prompts Anthem to re-examine the file, and in some states triggers a mandated re-review timeline.

One practical tactic: request a peer-to-peer review between the treating physician and Anthem's medical director before filing a formal internal appeal. Many PA denials for Prolia are overturned at the peer-to-peer stage when the prescriber discusses fracture risk, functional status, and prior bisphosphonate intolerance directly [2].

Prolia (Denosumab) for Indications Beyond Osteoporosis: Does Anthem Cover Them?

The FDA has approved denosumab under the brand name Xgeva (120 mg every 4 weeks subcutaneous) for prevention of skeletal-related events in adults with bone metastases from solid tumors, multiple myeloma, and giant cell tumor of bone [1]. Prolia 60 mg every 6 months is the formulation for osteoporosis indications only. Anthem covers Xgeva under oncology medical-benefit policies, which have separate PA criteria tied to oncology pathways.

Denosumab is not FDA-approved for weight loss, and no published randomized controlled trial demonstrates clinically meaningful body-weight reduction with this agent. Prolia works exclusively on bone-resorption pathways through RANK-ligand inhibition, not on adipose tissue, appetite regulation, or energy expenditure. Anthem will not cover Prolia for weight loss, and any such request will be denied as not meeting medical-necessity criteria [1].

Off-label use in premenopausal women with osteoporosis is supported by smaller trials. The FREEDOM extension data suggest sustained efficacy over 10 years [11], but coverage for premenopausal women requires individual PA with documentation of secondary osteoporosis (e.g., glucocorticoid use, anorexia nervosa, estrogen deficiency).

Cost Assistance When Anthem Coverage Falls Short

Amgen SupportPlus

Amgen offers the SupportPlus program for patients prescribed Prolia. For commercially insured patients, the co-pay card may reduce out-of-pocket cost to as low as $0 per dose, subject to a maximum annual benefit and eligibility restrictions. Patients enrolled in federal programs (Medicare, Medicaid, TRICARE) are not eligible for the co-pay card under federal anti-kickback rules [12].

Patient Assistance Program

Amgen's patient assistance program (Amgen Safety Net Foundation) provides Prolia at no cost to uninsured or underinsured patients who meet income criteria, generally at or below 500% of the federal poverty level. Applications are processed through the prescriber's office.

340B and Hospital-Based Clinics

Patients receiving Prolia at a 340B-covered entity (federally qualified health centers, certain hospital outpatient departments) may access the drug at significantly reduced cost regardless of insurance status, since 340B pricing applies to the provider's acquisition cost, not the patient's benefit tier.

Practical Documentation Checklist for Prescribers Seeking Anthem PA Approval

The following checklist summarizes the documentation that HealthRX's clinical team has found most effective in achieving first-pass Anthem PA approval for Prolia:

• DXA report dated within 24 months, with T-scores at lumbar spine (L1-L4) and total hip or femoral neck.
• FRAX calculation (available at sheffield.ac.uk/FRAX) with BMD input, printed or screenshot.
• For step-therapy bypass: radiology report confirming vertebral or hip fracture, or pharmacy-claims printout showing bisphosphonate fills with office note documenting adverse reaction.
• Serum 25-hydroxyvitamin D result (target above 30 ng/mL per Endocrine Society guidelines) [13].
• Serum calcium and eGFR within 90 days of the request.
• ICD-10-CM code matching the FDA-approved indication.
• Physician attestation letter (1 to 2 pages) citing AACE 2020 very-high-risk classification [5] and FREEDOM trial fracture-reduction data [4].
• Requested duration: 12 months (2 injections), which aligns with most Anthem PA authorization windows.

Submitting all items simultaneously at the initial PA request, rather than responding piecemeal to information requests, cuts average decision time and reduces the rate of automatic denials for incomplete submissions.

Stopping Denosumab: The Rebound Risk Anthem Reviewers Often Overlook

One clinical point that strengthens medical-necessity arguments: denosumab cannot be stopped without a transition plan. Unlike bisphosphonates, which incorporate into bone mineral and provide residual effect after discontinuation, denosumab's RANK-ligand inhibition is fully reversible. Bone turnover rebounds sharply within 6 to 12 months after the last dose, and multiple vertebral fractures have been reported in patients who missed injections or discontinued therapy without bridging to a bisphosphonate [14].

The FDA updated the Prolia label in 2022 to include a warning about multiple vertebral fractures following discontinuation [1]. The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "We suggest that after stopping denosumab, antiresorptive therapy be given to prevent rapid bone loss and multiple vertebral fractures." [15]

This discontinuation risk creates a clinical argument for Anthem approvals: once a patient is established on denosumab, arbitrary coverage interruptions due to formulary changes or authorization lapses carry documented fracture risk. Documenting that a patient is already on denosumab (continuation request rather than new start) and attaching the FDA label warning section often results in expedited approval.

Anthem Plan Variations Across States

Anthem operates under multiple subsidiary names. Coverage policies for Prolia follow Anthem's national clinical criteria document but may differ in step-therapy length, PA duration, and appeal timelines across states [6]:

• Anthem Blue Cross (California): California's step-therapy override law (SB 43, effective 2018) requires insurers to grant a step-therapy exception within 72 hours of an urgent request when clinically appropriate. This reduces effective step-therapy barriers.
• Empire BlueCross BlueCross BlueShield (New York): New York's external appeal law provides one of the strongest state-level IRO processes in the country, with legally binding decisions and timelines as short as 24 hours for urgent cases [9].
• Anthem Blue Cross and Blue Shield (Ohio, Indiana, Kentucky, Missouri, Wisconsin, Virginia, Georgia, Nevada, New Hampshire, Maine, Connecticut): These states follow federal ERISA rules for self-funded employer plans, which preempt state insurance mandates. Step-therapy duration and PA criteria are set by the employer's plan document, not state law.

Always verify the applicable plan document (Summary Plan Description for employer plans, or the Evidence of Coverage for ACA marketplace plans) before advising a patient on their specific rights.